En studie för att ge fortsatt tillgång till studier av droger till barn och ungdomar som har slutfört kliniska studier som involverar Gilead HIV-behandlingar
En öppen, enarmad studie för att ge fortsatt tillgång till studieläkemedel till deltagare som har slutfört pediatriska kliniska studier som involverar Gilead HIV-behandlingar
The goal of this clinical study is to provide continued access to the study drug(s) to children and adolescents with human immunodeficiency virus type 1 (HIV-1) who completed their participation in an applicable parent study and to monitor for adverse events.
The primary objectives of this study are as follows:
- To provide continued access to the study drug received in the parent protocol or switch to bictegravir/emtricitabine/tenofovir (B/F/TAF) for participants who completed a Gilead parent study evaluating drugs for HIV treatment.
- To evaluate the safety of the study drug(s) in participants with HIV-1.
Studieöversikt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
- Läkemedel: F/TAF (High Dose Tablet)
- Läkemedel: F/TAF (Low Dose Tablet)
- Läkemedel: F/TAF (Lowest Dose Tablet)
- Läkemedel: B/F/TAF (High Dose)
- Läkemedel: B/F/TAF (Low Dose)
- Läkemedel: B/F/TAF (High Dose TOS)
- Läkemedel: 3rd ARV Agent
- Läkemedel: E/C/F/TAF
- Läkemedel: E/C/F/TAF (Low Dose)
- Läkemedel: F/TAF (High Dose TOS)
- Läkemedel: F/TAF (Low Dose TOS)
- Läkemedel: F/TAF (Lowest Dose TOS)
- Läkemedel: Cobicistat (High Dose)
- Läkemedel: Cobicistat (Low Dose)
- Läkemedel: Cobicistat (TOS)
- Läkemedel: B/F/TAF (Low Dose TOS)
- Läkemedel: B/F/TAF (Lowest Dose TOS)
- Läkemedel: Nucleos(t)ide reverse transcriptase inhibitors (NRTI)
- Läkemedel: ATV
- Läkemedel: DRV
- Läkemedel: Lopinavir Boosted with ritonavir (LPV/r)
Studietyp
Studietyp
Inskrivning (Beräknad)
Inskrivning
Fas
Fas
- Fas 4
Kontakter och platser
Studiekontakt
Studiekontakt
- Namn: Gilead Clinical Study Information Center
- Telefonnummer: 1-833-445-3230 (GILEAD-0)
- E-post: GileadClinicalTrials@gilead.com
Studieorter
-
-
-
Buenos Aires, Argentina, C1141 ACG
- Avslutad
- Helios Salud
-
-
-
-
-
Panama City, Panama, 0816-00383
- Avslutad
- Hospital del Niño
-
-
-
-
-
Cape Town, Sydafrika, 7505
- Rekrytering
- University of Stellenbosch
-
Durban, Sydafrika, 3629
- Rekrytering
- Enhancing Care Foundation
-
Johannesburg, Sydafrika, 2112
- Rekrytering
- Rahima Moosa Mother and Child Hospital
-
Johannesburg, Sydafrika, 2038
- Rekrytering
- WITS RHI Research Centre
-
Paarl, Sydafrika, 7626
- Rekrytering
- Be Part Yoluntu Centre
-
Pretoria, Sydafrika, 0087
- Rekrytering
- The Aurun Institute
-
Soweto, Sydafrika, 2013
- Rekrytering
- Perinatal HIV Research Unit
-
-
-
-
-
Bangkok Noi, Thailand, 10700
- Aktiv, inte rekryterande
- Faculty of Medicine - Mahidol University
-
Khon Kaen, Thailand, 40002
- Aktiv, inte rekryterande
- Khon Kaen University
-
-
-
-
-
Kampala, Uganda, 10005
- Rekrytering
- Joint Clinical Research Centre
-
Kampala, Uganda, 256
- Rekrytering
- MU-JHU Research Collaboration/MU-JHU Care Ltd
-
Kampala, Uganda
- Rekrytering
- Baylor College of Medicine
-
Kampala, Uganda
- Rekrytering
- Strengthening Institutional Capacity for Research Administration (SICRA)
-
Masaka, Uganda
- Rekrytering
- Africa Medical and Behavioral Sciences Organisation
-
-
-
-
-
Harare, Zimbabwe
- Rekrytering
- University of Zimbabwe Clinical Research Centre
-
-
Deltagandekriterier
Urvalskriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Key Inclusion Criteria:
- Completed an applicable parent study: GS-US-292-0106, GS-US-380-1474, GS-US-311-1269, or GS-US-216-0128, and gave consent to study participation.
Key Exclusion Criteria:
-
Individuals planning to switch to B/F/TAF on Day 1 with plasma HIV RNA ≥ 50 copies/mL during the last parent study visit prior to screening/Day 1 visit.
- Note: individuals planning to switch after Day 1 must not have plasma HIV RNA ≥ 50 copies/mL (or detectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL).
-
Individuals planning to switch to B/F/TAF with any ongoing Grade 3 or 4 drug-related AE or clinically relevant Grade 3 or 4 drug-related laboratory abnormality (confirmed on repeat) related to any component of B/F/TAF prior to treatment switch.
-
For those on B/F/TAF or planning to switch to B/F/TAF: previous treatment discontinuation of any component of B/F/TAF due to toxicity or intolerance.
-
For those planning to switch to B/F/TAF: known hypersensitivity to any component of the study drug, its metabolites, or formulation excipients.
-
Ongoing treatment with or prior use of any prohibited medications.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Antal vapen
Vapen och interventioner
Deltagargrupp / ArmDeltagargrupp / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Experimentell: Rollover from Parent Study: GS-US-311-1269: Parent Study Drug (F/TAF) or B/F/TAF
Participants will continue to take the study drug they were taking in the parent study, emtricitabine/tenofovir alafenamide (F/TAF) along with a 3rd antiretroviral (ARV) agent. The dose of F/TAF will be based on the weight of the participant, ranging between 120/15 mg to 200/25 mg. The dose of F/TAF will be different when given with the boosted and the unboosted 3rd ARV agent: F/TAF (High Dose Tablet) for unboosted 3rd ARV agent; F/TAF (Low Dose Tablet) for the boosted 3rd ARV agent. Participants may switch to B/F/TAF, at a dose based on participant's weight. |
200/25 mg fixed-dose combination (FDC) tablet administered orally
Andra namn:
200/10 mg FDC tablet administered orally 120/15 mg FDC tablet administered orally 50/200/25 mg FDC tablet administered orally
Andra namn:
30/120/15 mg FDC tablet administered orally
Andra namn:
15/60/7.52 mg TOS administered orally
Andra namn:
A 3rd antiretroviral (ARV) agent administered as defined by the investigator, according to the prescribing information. A 3rd ARV agent may include: boosted atazanavir (ATV), boosted lopinavir (LPV/r), boosted darunavir (DRV), unboosted efavirenz (EFV), unboosted nevirapine (NVP), unboosted raltegravir (RAL), or unboosted dolutegravir (DTG), or any other unspecified agent that is available in a participant's country |
|
Experimentell: Rollover from Parent Study: GS-US-292-0106: Parent Study Drug (E/C/F/TAF) or B/F/TAF
Participants will continue to take the study drug they were taking in the parent study, elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF). The dose of E/C/F/TAF will be based on the weight of the participant, ranging between 90/90/120/6 mg to 150/150/200/10 mg. Participants may switch to B/F/TAF at a dose based on participant's weight. |
50/200/25 mg FDC tablet administered orally
Andra namn:
30/120/15 mg FDC tablet administered orally
Andra namn:
150/150/200/10 mg tablet administered orally
Andra namn:
90/90/120/6 mg tablet administered orally |
|
Experimentell: Rollover Parent Study GS-US-216-0128: Parent Study Drug (Combination Drugs) or B/F/TAF
Participants will continue to take the following study drugs they were taking in the parent study:
The dose of F/TAF will be based on the weight of the participant, ranging between 15/1.88 mg and 200/25 mg, once daily. Additionally, the dose of COBI will be based on the weight of the participant, ranging between 30 mg and 150 mg, once or twice daily. Participants may switch to B/F/TAF at a dose based on participant's weight. |
200/25 mg fixed-dose combination (FDC) tablet administered orally
Andra namn:
120/15 mg FDC tablet administered orally 50/200/25 mg FDC tablet administered orally
Andra namn:
30/120/15 mg FDC tablet administered orally
Andra namn:
15/60/7.52 mg TOS administered orally
Andra namn:
A 3rd antiretroviral (ARV) agent administered as defined by the investigator, according to the prescribing information. A 3rd ARV agent may include: boosted atazanavir (ATV), boosted lopinavir (LPV/r), boosted darunavir (DRV), unboosted efavirenz (EFV), unboosted nevirapine (NVP), unboosted raltegravir (RAL), or unboosted dolutegravir (DTG), or any other unspecified agent that is available in a participant's country 60/7.5 mg tablet for oral suspension (TOS) administered orally 30/3.75 mg TOS administered orally 15/1.88 mg TOS administered orally 150 mg tablet administered orally
Andra namn:
90 mg tablet administered orally
Andra namn:
30 mg TOS administered orally
Andra namn:
7.5/30/3.76 mg TOS administered orally
Andra namn:
3.76/15/1.88 mg TOS administered orally
Andra namn:
NRTIs administered as defined by the investigator, according to the prescribing information. NRTIs may include zidovudine (ZDV), stavudine (d4T), didanosine (ddI), abacavir (ABC), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), lamivudine (3TC), or emtricitabine (FTC) Administered according to the prescribing information Administered according to the prescribing information Administered according to the prescribing information |
|
Experimentell: Rollover from Parent Studies: GS-US-380-1474 and CO-US-380-5578: Parent Study Drug (B/F/TAF)
Participants will continue to take the study drug they were taking in the parent study, B/F/TAF. Participants who are diagnosed with HIV-1 infection in parent study CO-US-380-5578 and complete the study drug will continue to take the study drug they were taking in the parent study, B/F/TAF. The dose of B/F/TAF will be based on the weight of the participant. |
50/200/25 mg FDC tablet administered orally
Andra namn:
30/120/15 mg FDC tablet administered orally
Andra namn:
15/60/7.52 mg TOS administered orally
Andra namn:
7.5/30/3.76 mg TOS administered orally
Andra namn:
3.76/15/1.88 mg TOS administered orally
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Number of Eligible Participants Who Have Received Access to the Study Drug(s) in the Study
Tidsram: Up to 2.8 Years
|
Up to 2.8 Years
|
Sekundära resultatmått
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Andel deltagare som upplever behandlingsuppkommande biverkningar (TEAE)
Tidsram: Upp till 9,5 år
|
Upp till 9,5 år
|
Samarbetspartners och utredare
Sponsor
Sponsor
Utredare
Utredare
- Studierektor: Gilead Study Director, Gilead Sciences
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Studiestart
Primärt slutförande (Beräknad)
Primärt slutförande
Avslutad studie (Beräknad)
Avslutad studie
Studieregistreringsdatum
Först inskickad
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Första postat
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste uppdatering publicerad
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Svavelföreningar
- Organiska kemikalier
- Heterocykliska föreningar, 1-ring
- Heterocykliska föreningar
- Heterocykliska föreningar, 2-ring
- Heterocykliska föreningar, smältring
- Farmaceutiska förberedelser
- Doseringsformer
- Tiazoler
- Azoler
- Nukleinsyror, nukleotider och nukleosider
- Syror, acykliska
- Karboxylsyror
- Puriner
- Deoxycytidin
- Cytidin
- Pyrimidin nukleosider
- Pyrimidiner
- Organofosforföreningar
- Nukleosider
- Deoxyribonukleosider
- Organofosfonater
- Adenin
- Narkotikakombinationer
- Tenofovir
- Emtricitabin
- Karbamater
- Cobicistat
- Elvitegravir, Cobicistat, Emtricitabin, Tenofovir Disoproxil Fumarate Läkemedelskombination
- Ritonavir
- Tabletter
- bictegravir, emtricitabine, tenofovir alafenamide, läkemedelskombination
- emtricitabin tenofovir alafenamid
Andra studie-ID-nummer
Andra studie-ID-nummer
- GS-US-380-6684
- 2024-000521-40 (Annan identifierare: European Medicines Agency)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .